← Back to Clinical Trials
Recruiting Phase 3 NCT06974851

A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity

Trial Parameters

Condition Bstructive Sleep Apnea (OSA) and Obesity
Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 140
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2025-07-25
Completion 2026-12
Interventions
HRS9531HRS9531placebo

Brief Summary

A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects with Obstructive Sleep Apnea (OSA) and Obesity

Eligibility Criteria

Inclusion Criteria: 1. The participant has provided informed consent and is willing and able to comply with the study protocol requirements to complete the study. 2. Age between 18 and 75 years, male or female, at the time of signing the informed consent form. 3. BMI ≥ 28.0 kg/m² at screening. 4. Has been on a controlled diet and exercise regimen for 3 months or more, with a weight change of ≤ 5.0 kg in the past 3 months. 5. Polysomnography (PSG) results at screening confirm OSA. 6. Female participants of childbearing potential and male participants with partners of childbearing potential agree to use highly effective contraception from the time of signing the informed consent form until 2 months after the last dose, with no plans for pregnancy or donation of eggs/sperm during this period. Female participants of childbearing potential must have a negative pregnancy test within 3 days prior to randomization and must not be breastfeeding. Exclusion Criteria: 1. Laboratory Test Abnormalit

Related Trials